登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H25ClN2O5 · C6H5SO3H
化学文摘社编号:
分子量:
567.05
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)
SMILES string
OS(=O)(=O)c1ccccc1.CCOC(=O)C2=C(COCCN)NC(C)=C(C2c3ccccc3Cl)C(=O)OC
InChI key
ZPBWCRDSRKPIDG-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
amlodipine
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)
正在寻找类似产品? 访问 产品对比指南
General description
本产品按照现行药典要求提供和指定。所有为支持本产品而提供的信息，包括 SDS 和任何产品信息小册子，均由药典颁发机构制定和发布。如需进一步的信息和支持，请访问现行药典网站。如需进一步信息和支持，请访问现行药典网站。
Application
苯磺酸氨氯地平USP参考标准品，预期用途是USP规定的指定质量测试和检测。也用于USP各论，例如：
- 氨氯地平和阿托伐他汀片
- 氨氯地平和盐酸贝那普利胶囊
- 氨氯地平和奥美沙坦酯片
- 氨氯地平和缬沙坦片
- 氨氯地平苯磺酸盐
- 氨氯地平苯磺酸盐片
- 氨氯地平复方口服混悬液
Biochem/physiol Actions
氨氯地平是一种 L 型钙通道阻滞剂。氨氯地平属于一类心血管药物，作用于 Ca V 1 或 L 型的电压门控钙通道。氨氯地平还具有降压和抗心绞痛作用。其活性主要存在于 (-)-异构体中。氨氯地平抑制人表皮样癌细胞 A431 的生长，对雄性大鼠有抗生殖作用。
苯磺酸氨氯地平是一种 L 型钙通道阻滞剂。
Analysis Note
这些产品仅供测试和分析使用。它们不适用于人类或动物的给药，不可用于诊断、治疗或治愈任何疾病。
Other Notes
可能适用相应的销售限制。
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
C Venkata S Ram
Expert review of cardiovascular therapy, 9(1), 9-19 (2010-12-21)
Hypertension is an increasingly prevalent cardiovascular risk factor associated with high rates of morbidity and mortality. Lowering blood pressure (BP) to recommended levels reduces the risk of hypertension-associated cardiovascular events. Despite current treatment options and recommendations, the BP of many
Amlodipine besylate.
Gennady Ananchenko et al.
Profiles of drug substances, excipients, and related methodology, 37, 31-77 (2012-04-04)
Rishi Puri et al.
Journal of the American College of Cardiology, 65(13), 1273-1282 (2015-04-04)
Statins can regress coronary atheroma and lower clinical events. Although pre-clinical studies suggest procalcific effects of statins in vitro, it remains unclear if statins can modulate coronary atheroma calcification in vivo. This study compared changes in coronary atheroma volume and calcium indices
Eun Young Lee et al.
Rheumatology (Oxford, England), 53(4), 658-664 (2013-12-20)
RP is a reversible vasoconstriction of digital arteries that causes pain and skin discoloration. This study compared the efficacy of the new phosphodiesterase type 5 inhibitor udenafil with that of the calcium channel blocker amlodipine in the treatment of secondary
J M Krzesinski et al.
Revue medicale de Liege, 62(11), 688-694 (2008-01-26)
Hypertension is a common treatable risk factor for cardiovascular disease. Even when identified and treated, most patients with hypertension do not get to blood pressure goal and they often need at least two antihypertensive agents to achieve blood pressure control.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持